Recent Advances in Signaling Pathways and Kinase Inhibitors for Leukemia Chemotherapy

Title:Recent Advances in Signaling Pathways and Kinase Inhibitors for Leukemia Chemotherapy

Volume: 31

Author(s): Yuying Liu, Zeyu Yang, Qingqing Zhang, Ping Hai, Yongbiao Zheng, Jie Zhang and Xiaoyan Pan*

Affiliation:

• School of Pharmacy, Health Science Center, Xi’an Jiaotong University, Xi'an, 710061, China

Keywords: leukemia, signal pathway, protein kinase, inhibitors

Abstract: Leukemia is a malignant clonal disease of hematopoietic stem cells, which accounts for about 3% of the total incidence of tumors and is particularly prevalent among children and adolescents. It mainly includes four types of leukemia, namely ALL, AML, CLL, and CML, which are often aggressive and challenging diseases to treat. Several signaling pathways are dysregulated in almost all types of leukemia, such as JAK, PI3K, and MAPK, and others are dysregulated in specific types of leukemia, like Wnt/β-catenin, Hedgehog, FLT3, Bcr-Abl, and so on. Many efforts have been devoted to developing small molecule inhibitors targeting protein kinases involved in leukemia-related signaling pathways. In this review, we focus on the study of signaling pathways and protein kinases that developed as targets of anti-leukemia drug therapy and report the research progress of relevant small molecule kinase inhibitors over the last five years.

Cite this article as:

Liu Yuying, Yang Zeyu, Zhang Qingqing, Hai Ping, Zheng Yongbiao, Zhang Jie and Pan Xiaoyan*, Recent Advances in Signaling Pathways and Kinase Inhibitors for Leukemia Chemotherapy, Current Medicinal Chemistry 2024; 31 () . https://dx.doi.org/10.2174/0109298673267738231129104216